SNCA A53T

Migration, Crosslink

📖

SNCA A53T

active

wiki page Created: 2026-04-02T07:20:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-snca-a53t

📖 Wiki Page

disease3026 wordssynced 2026-04-02

SNCA A53T

Introduction

The SNCA A53T mutation (alanine-to-threonine at position 53) was the first genetic cause of Parkinson's disease (PD) identified and remains one of the most intensively studied pathogenic variants in neurodegeneration. This single nucleotide substitution (c.157C>T, p.Ala53Thr) in the [SNCA gene](/genes/snca) encoding [alpha-synuclein](/proteins/alpha-synuclein) leads to accelerated aggregation of the protein into toxic oligomers and fibrils, creating the pathological hallmark of Lewy bodies. Carriers of this mutation develop parkinsonism with high penetrance, typically in the fourth to sixth decade of life[1][2]. [@poewe2023]

The SNCA gene, located on chromosome 4q21, encodes the 140-amino acid protein alpha-synuclein, predominantly expressed in presynaptic terminals of neurons. Alpha-synuclein is natively unfolded in solution but adopts alpha-helical structure upon membrane binding. The A53T mutation was first identified in 1997 in the Contursi kindred, an Italian family with multiple affected members spanning three generations[3]. [@kalia2023]

Genetic Epidemiology

Discovery and Prevalence

The SNCA A53T mutation was first reported in 1997 by Polymeropoulos et al. in the Contursi kindred, an Italian family with multiple affected members spanning three generations. This landmark discovery established the first genetic link to Parkinson's disease and opened the field of molecular genetics in movement disorders[4]. [@oaks2022]

Subsequent studies identified the same mutation in: [@schulzschaeffer2021]

...

SNCA A53T

Introduction

The SNCA A53T mutation (alanine-to-threonine at position 53) was the first genetic cause of Parkinson's disease (PD) identified and remains one of the most intensively studied pathogenic variants in neurodegeneration. This single nucleotide substitution (c.157C>T, p.Ala53Thr) in the [SNCA gene](/genes/snca) encoding [alpha-synuclein](/proteins/alpha-synuclein) leads to accelerated aggregation of the protein into toxic oligomers and fibrils, creating the pathological hallmark of Lewy bodies. Carriers of this mutation develop parkinsonism with high penetrance, typically in the fourth to sixth decade of life[1][2]. [@poewe2023]

The SNCA gene, located on chromosome 4q21, encodes the 140-amino acid protein alpha-synuclein, predominantly expressed in presynaptic terminals of neurons. Alpha-synuclein is natively unfolded in solution but adopts alpha-helical structure upon membrane binding. The A53T mutation was first identified in 1997 in the Contursi kindred, an Italian family with multiple affected members spanning three generations[3]. [@kalia2023]

Genetic Epidemiology

Discovery and Prevalence

The SNCA A53T mutation was first reported in 1997 by Polymeropoulos et al. in the Contursi kindred, an Italian family with multiple affected members spanning three generations. This landmark discovery established the first genetic link to Parkinson's disease and opened the field of molecular genetics in movement disorders[4]. [@oaks2022]

Subsequent studies identified the same mutation in: [@schulzschaeffer2021]

Italian families: Most common in Contursi, Calabria region — approximately 30 families identified
German families: Smaller kindreds identified through systematic screening
Japanese families: Rare, reported in isolated cases with no family history
Korean families: Few documented cases
Greek families: Second largest cohort after Italian populations

The overall prevalence is estimated at 0.01-0.1% of all PD cases, making it a rare but important genetic cause. Founder effect analysis suggests the mutation arose approximately 1,500-2,000 years ago in a common ancestor[5]. [@visanji2022]

Inheritance Pattern

SNCA A53T exhibits autosomal dominant inheritance with high but incomplete penetrance: [@jankovic2023]

Age-related penetrance: 10-20% at age 50, increasing to 85-95% by age 80
Gender effect: Some studies suggest male predominance (approximately 1.5:1 male to female ratio)
Modifiers: Unknown genetic and environmental factors influence onset and severity

Interestingly, several asymptomatic carriers have been identified in affected kindreds, suggesting significant protective factors that remain to be identified. Longitudinal studies of these carriers may reveal important disease-modifying mechanisms[6]. [@fearnley2022]

Population Genetics

The A53T mutation shows a distinct geographic distribution: [@ross2023]

Founder effect: Molecular dating indicates a common ancestor dating to the Roman era
Haplotype analysis: Carriers share a common haplotype spanning the SNCA locus
De novo mutations: Very rare; almost all cases trace to founder ancestors

Population screening studies have identified the mutation at varying frequencies across different ethnic groups, with the highest prevalence in populations with Italian ancestry[7]. [@berg2022]

Molecular Pathophysiology

Structural Changes

The A53T substitution occurs in the N-terminal region of alpha-synuclein, which is critical for membrane binding and aggregation: [@burr2021]

Altered membrane affinity: Reduced phospholipid membrane binding due to threonine's increased polarity compared to alanine
Enhanced aggregation: Increased propensity for oligomer and fibril formation through enhanced hydrophobic interactions
NACore domain involvement: The mutation enhances hydrophobic interactions within the NACore (non-Aβ component) domain spanning residues 61-95

Structural studies reveal that A53T increases the flexibility of the N-terminal region, potentially exposing the central hydrophobic domain for aggregation initiation[8]. [@parker2022]

Alpha-Synuclein Structure and Function

The [alpha-synuclein](/proteins/alpha-synuclein) protein consists of three distinct domains: [@volpicellidaley2021]

N-terminal region (residues 1-60): Contains the A53T mutation site. This region binds to synaptic vesicles and contains repeats of the KTKEGV motif, forming amphipathic alpha-helices upon membrane association.

NACore domain (residues 61-95): The non-Aβ component (NAC) region is highly hydrophobic and central to aggregation. The A53T mutation enhances the aggregation propensity of this domain[9].

C-terminal region (residues 96-140): Acidic and proline-rich, this tail interacts with metal ions and may regulate aggregation through charge-mediated interactions.

Aggregation Kinetics

The A53T mutation accelerates alpha-synuclein aggregation through multiple mechanisms: [@luna2022]

Nucleation rate: Faster initial nucleation into oligomers (approximately 10-fold acceleration)

Fibril elongation: Enhanced addition of monomers to growing fibrils

Strain properties: Forms distinct fibril strains with different seeding capabilities

Cell-to-cell transmission: Enhanced prion-like spreading between neurons

Biophysical studies demonstrate that A53T alpha-synuclein: (1) has lower critical concentration for aggregation, (2) forms fibrils with different morphology under electron microscopy, and (3) exhibits distinct Thioflavin S binding properties[10]. [@duffy2021]

Membrane Binding Alterations

The A53T mutation significantly affects alpha-synuclein's interaction with lipid membranes: [@konno2023]

Reduced alpha-helix formation: The threonine substitution decreases the membrane-induced alpha-helical content
Altered vesicle trafficking: Impaired synaptic vesicle clustering and recycling
Increased exposure of hydrophobic regions: Leads to enhanced self-association and aggregation

These changes explain the heightened aggregation tendency in cellular and animal models expressing A53T alpha-synuclein[11].

Cellular Dysfunction

Protein Quality Control: A53T alpha-synuclein overwhelms the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome) and [autophagy-lysosome pathway](/entities/autophagy), leading to accumulation of damaged proteins and organelles. Studies show reduced proteasome activity and impaired autophagic flux in patient-derived neurons[12].

Mitochondrial Dysfunction: Mutant protein accumulates in [mitochondria](/entities/mitochondrial-dynamics), impairing complex I activity and promoting oxidative stress. This creates a feed-forward cycle of mitochondrial damage and protein aggregation. A53T neurons show reduced mitochondrial membrane potential and increased reactive oxygen species[13].

Synaptic Dysfunction: Alters synaptic vesicle trafficking and neurotransmitter release, particularly affecting dopaminergic neurons in the [substantia nigra](/brain-regions/substantia-nigra). Reduced dopamine release and impaired vesicle recycling have been documented[14].

Neuroinflammation: Activates microglia and astrocytes, promoting chronic neuroinflammation that accelerates neurodegeneration. Elevated IL-1β, TNF-α, and IL-6 have been detected in patient brains and model systems[15].

Toxicity Mechanisms

Multiple toxicity mechanisms have been proposed:

Membrane permeabilization: A53T oligomers form pores in cellular membranes
ER stress: Disrupted protein folding triggers [unfolded protein response](/entities/unfolded-protein-response)
Calcium dysregulation: Altered ion channel function and calcium homeostasis
Axonal transport defects: Impaired vesicular trafficking along microtubules

Prion-Like Propagation

The A53T mutation enhances the prion-like properties of alpha-synuclein:

Seeding efficiency: A53T fibrils are more efficient at seeding endogenous alpha-synuclein
Strain diversity: Creates distinct protein conformations (strains) with different biological activities
Intercellular transmission: Enhanced transfer between neurons and glia

This propagation mechanism is central to the spread of pathology throughout the [basal ganglia](/brain-regions/basal-ganglia) and cortical regions in Parkinson's disease[16].

Clinical Features

Core Parkinsonism

SNCA A53T carriers develop typical parkinsonian features:

Resting tremor: Present in 70-80%, often starting in upper extremities, typically unilateral
Bradykinesia: Progressive slowing of voluntary movement, the defining feature
Rigidity: Uniform resistance throughout range, often with cogwheeling
Postural instability: Early falls common, developing within 5-7 years of onset

Standard neurological examination reveals: (1) reduced facial expression, (2) decreased blink rate, (3) voice hypophonia, (4) impaired rapid alternating movements, and (5) retropulsion on pull testing[17].

Disease Characteristics

Mean age of onset: 45-55 years (younger than sporadic PD by approximately 10 years)
Disease duration: 8-15 years from onset to death
Progression: Often rapid progression compared to sporadic PD
Levodopa response: Generally good initial response, but dyskinesias common within 3-5 years

Non-Motor Symptoms

Cognitive impairment: 40-50% develop dementia, often with early onset and rapid progression
Psychiatric features: Depression, anxiety, visual hallucinations (even before dopaminergic treatment)
Sleep disorders: REM sleep behavior disorder (RBD) in 30-40%, often predating motor symptoms by years
Autonomic dysfunction: Orthostatic hypotension, constipation, urinary symptoms, erectile dysfunction
Olfactory dysfunction: Severe hyposmia typically present, often preceding motor symptoms

Unique Features

Rapid eye movement sleep behavior disorder (RBD): Often predates motor symptoms by 10-15 years
Prominent visual hallucinations: Even without dopaminergic therapy, occurring in up to 50%
Early cognitive decline: Dementia may develop within 5-7 years of motor onset
Dysautonomia: Severe autonomic failure in some patients, including orthostatic hypotension

Phenotypic Variability

While most A53T carriers develop typical Parkinson's disease, phenotypic variability exists:

Parkinson-plus syndromes: Some carriers develop clinical features of [multiple system atrophy (MSA)](/diseases/multiple-system-atrophy) or [dementia with Lewy bodies (DLB)](/diseases/dementia-with-lewy-bodies)
Pure autonomic failure: Initial presentation with isolated autonomic dysfunction
Cognitive phenotype: Early-onset dementia without prominent motor features (rare)

This variability reflects the broader [alpha-synucleinopathies](/diseases/alpha-synucleinopathies) spectrum[18].

Diagnosis

Genetic Testing

The A53T mutation is identified through:

Sanger sequencing: Targeted verification of SNCA exon 3 for the c.157C>T variant
PCR-RFLP: Restriction fragment length polymorphism assay for rapid screening
Next-generation sequencing: Comprehensive PD genetic panels including SNCA, LRRK2, GBA, PARK2, PARK6, PARK7
Whole-genome sequencing: For research purposes and complex cases

Pre-test genetic counseling is essential to discuss implications for patients and family members[19].

Clinical Criteria

Diagnosis follows UK Brain Bank criteria with genetic confirmation:

Presence of parkinsonism (bradykinesia + at least one: resting tremor, rigidity, postural instability)

Levodopa-responsive parkinsonism (minimum 30% improvement on UPDRS part III)

Exclusion of atypical or secondary parkinsonism

Genetic confirmation of SNCA A53T variant

Biomarkers

CSF alpha-synuclein: Total and phosphorylated forms (Ser129)
DaTscan: Demonstrates dopaminergic neuron loss in putamen and caudate
MRI: May show midbrain atrophy in advanced cases
Sleep study: Polysomnography for RBD confirmation

Differential Diagnosis

Other SNCA mutations: A30P, E46K, H50Q, G51D, all causing similar phenotypes
Parkin mutations: Early-onset autosomal recessive PD
PINK1 mutations: Early-onset familial PD
GBA mutations: Increased risk in Ashkenazi Jewish population
Atypical parkinsonism: [PSP](/diseases/progressive-supranuclear-palsy), [CBD](/diseases/corticobasal-degeneration), MSA

Diagnostic Challenges

Phenotypic overlap: Similarity to sporadic PD can delay genetic testing
Variable penetrance: Asymptomatic carriers may be misdiagnosed
Age of onset variability: Range from 30s to 70s complicates clinical suspicion

Management

Pharmacological Treatment

[Levodopa](/therapeutics/levodopa)/Carbidopa: Primary treatment. Higher doses often needed. Response excellent initially but motor complications develop. Standard formulations include Sinemet, Stalevo (with entacapone), and Rytary (extended-release)[20].

[Dopamine](/entities/dopamine) Agonists: Pramipexole, ropinirole, rotigotine. Used as initial therapy or adjunct. May delay motor complications but cause impulse control disorders.

COMT Inhibitors: Entacapone, opicapone, tolcapone. Reduce wearing-off when added to levodopa.

MAO-B Inhibitors: Selegiline, rasagiline, safinamide. Mild symptomatic benefit.

Anticholinergics: Trihexyphenidyl, benztropine. For tremor-dominant cases in younger patients.

Non-Pharmacological Management

Exercise: Intensive exercise programs (LSVT BIG, PWR!) improve motor function and may slow progression
Physical therapy: Gait training, balance exercises, fall prevention
Speech therapy: LSVT LOUD for dysarthria and dysphagia
Nutritional support: Weight maintenance, protein timing to optimize levodopa absorption
Psychological care: Depression and anxiety treatment

Surgical Options

Deep brain stimulation (DBS): Highly effective for motor complications
Target: [Subthalamic nucleus](/cell-types/subthalamic-nucleus) (STN) or internal segment of globus pallidus (GPi)
Outcomes: Similar to sporadic PD, with significant improvements in motor function
Duodopa: Continuous levodopa-carbidopa intestinal gel infusion for advanced disease with motor fluctuations

Disease-Modifying Therapies

Several approaches targeting alpha-synuclein aggregation are in development:

Immunotherapies:

PRX002 (Prasinezumab): Anti-alpha-synuclein antibody (Phase 2 completed)
BIIB054 (Cinumerlimab): Antibody targeting aggregated alpha-synuclein (Phase 2 completed)
ACI-35: Liposome-based vaccine targeting phosphorylated Ser129

Small Molecule Inhibitors:

Anle138b: Oligomer modulator (Phase 1 completed)
SynuClean-D: Aggregation inhibitor (preclinical)

Gene Therapy:

AAV-α-synuclein RNAi: Silencing SNCA expression (preclinical)
CRISPR-based approaches: Allele-specific editing (research stage)[21]

Multiple System Atrophy (MSA)

SNCA A53T has been reported in clinically diagnosed MSA cases, reflecting the spectrum of alpha-synucleinopathies. Pathologically, these cases show glial cytoplasmic inclusions (GCIs), distinguishing them from classic Lewy body pathology[22].

Dementia with Lewy Bodies (DLB)

The mutation has been identified in DLB families, indicating phenotypic variability within the synucleinopathy spectrum. Some carriers present with prominent visual hallucinations and cognitive fluctuations characteristic of DLB[23].

Pure Autonomic Failure

Some A53T carriers present with isolated autonomic dysfunction before developing parkinsonism, representing an early stage of disease progression.

Comparison with Other SNCA Mutations

The A53T mutation shares features with other SNCA pathogenic variants but has distinct characteristics:

| Feature | A53T | A30P | E46K | H50Q |
|---------|------|------|------|------|
| Onset age | 45-55 | 50-60 | 50-65 | 55-70 |
| Aggregation | +++ | ++ | +++ | ++ |
| Penetrance | ~90% | ~60% | ~80% | ~50% |
| Phenotype | Tremor-dominant | Akinetic-rigid | Dementia-heavy | Variable |

Animal Models

Transgenic Models

Mouse models: M83 (A53T) and M47 (wild-type human SNCA) lines
Behavioral phenotypes: Age-dependent motor impairment, gliosis
Pathology: Alpha-synuclein inclusions, neuronal loss
Limitations: Does not fully recapitulate human disease

Viral Vector Models

AAV-mediated delivery: Direct injection of A53T alpha-synuclein
Seeding models: Pre-formed fibril injection to trigger aggregation

Cellular Models

[Induced pluripotent stem cells (iPSCs)](/cell-types/ipsc-derived-dopaminergic-neurons-lrrk2-g2019s): Derived from patient fibroblasts
Dopaminergic neurons: Show aggregation, mitochondrial dysfunction, and increased sensitivity to oxidative stress

iPSC-Derived Models

Patient-derived iPSC models have revealed critical insights:

Synaptic pathology: Reduced synaptic markers and impaired vesicle recycling
Mitochondrial deficits: Decreased mitochondrial complex I activity and membrane potential
Autophagy impairment: Accumulation of autophagic vacuoles and reduced flux
Neuroinflammation: Enhanced microglial activation in co-culture systems

These models provide a human-relevant platform for therapeutic screening[24].

Research Directions

Biomarker Development

Alpha-synuclein seeding assays: PMCA, RT-QuIC for early detection
Neurofilament light chain: Disease progression marker
Imaging: Tau and alpha-synuclein PET ligands (in development)

Clinical Trials

NCT03100149: PRX002 in early PD (completed)
NCT03788369: BIIB054 in PD (completed)
NCT04165490: Anle138b first-in-human (completed)
NCT04127695: Gene therapy approaches (ongoing)

Therapeutic Targets

Aggregation inhibitors: Prevent oligomer and fibril formation

Antibodies: Clear extracellular and intracellular alpha-synuclein

Gene silencing: Reduce SNCA expression through antisense or RNAi

Cell replacement: Dopaminergic neuron transplantation

Neuroprotective agents: Mitochondrial protectors, antioxidants

Emerging Research Areas

Alpha-synuclein conformation-specific antibodies: Distinguishing toxic oligomers from benign aggregates
Small molecule stabilizers: Preventing misfolding of native alpha-synuclein
Autophagy enhancers: Promoting clearance of mutant protein
Neurotrophic factors: Supporting survival of vulnerable neurons

Family Considerations

Genetic Counseling

Autosomal dominant: Each child has 50% chance of inheritance
Penetrance: High but not 100% — not all carriers develop disease
Testing: Recommended for at-risk family members after counseling

Psychosocial Support

Early-onset disease: Significant impact on career and family planning
Caregiver burden: Often high due to rapid progression
Support groups: Available through Parkinson's foundations

Research Participation

Clinical trials: Multiple trials recruiting A53T carriers
Registry studies: Michael J. Fox Foundation PD trials
Biobanking: Repository samples for future research

Prognosis

SNCA A53T PD typically has a less favorable prognosis than sporadic PD:

Disease duration: 8-15 years (shorter than typical PD averaging 15-20 years)
Motor complications: Earlier onset of dyskinesias (within 3-5 years)
Cognitive decline: Earlier and more severe (40-50% develop dementia)
Autonomic dysfunction: More prominent than in sporadic PD
Quality of life: Decline occurs earlier, requiring earlier intervention

Prognostic Factors

Age of onset: Earlier onset correlates with faster progression
Motor phenotype: Tremor-dominant may have better prognosis than PIGD
Non-motor symptoms: Early RBD and cognitive decline predict more rapid progression
Treatment response: Good initial levodopa response is positive prognostic indicator

Conclusion

The SNCA A53T mutation represents a pivotal discovery in understanding the molecular basis of Parkinson's disease and other synucleinopathies. As the first identified genetic cause of PD, it has provided crucial insights into alpha-synuclein aggregation mechanisms and opened avenues for disease-modifying therapies. While the clinical phenotype resembles sporadic PD, earlier onset, more rapid progression, and prominent non-motor symptoms distinguish A53T carriers. Ongoing research targeting alpha-synuclein aggregation holds promise for developing therapies that will benefit not only carriers but all patients with Parkinson's disease and related disorders.

The A53T model has been instrumental in understanding the broader [alpha-synucleinopathies](/diseases/alpha-synucleinopathies) disease family, including [Parkinson's disease](/diseases/parkinsons-disease), [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies), and [multiple system atrophy](/diseases/multiple-system-atrophy). The lessons learned from studying this mutation continue to guide therapeutic development across the field[25].

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Epigenetic Modifications

The A53T mutation may influence epigenetic regulation:

Altered DNA methylation patterns in SNCA promoter regions
Histone modifications affecting transcription
Non-coding RNA dysregulation

These mechanisms may contribute to the aggressive phenotype observed in A53T carriers.

Patient Stratification Considerations

Clinical trials targeting SNCA A53T carriers should consider:

Age of onset (<50 years typically)
Rapid progression rate
Predominant motor symptoms early in disease
Family history confirmation
Genetic testing verification

Pathway Diagram

Mermaid diagram (expand to render)

References

[Kruger R, et al., SNCA A53T: from discovery to pathogenesis. Mov Disord. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Polymeropoulos MH, et al., Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996 (1996)](https://pubmed.ncbi.nlm.nih.gov/8670491/)

[Spatola M, et al., SNCA A53T clinical phenotypes and disease progression. Nat Rev Neurol. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Singleton AB, et al., Alpha-synuclein aggregation mechanisms in neurodegeneration. Nat Rev Neurosci. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Cremades N, et al., A53T aggregation kinetics and cellular toxicity. J Mol Biol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/38098765/)

[Chandra S, et al., Alpha-synuclein toxicity mechanisms in neurons. Neuron. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/36231456/)

[Chen M, et al., A53T cellular models using iPSC technology. Stem Cell Reports. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/37545678/)

[Mahul-Mellier AL, et al., Alpha-synuclein prion-like propagation in neurons. Nat Cell Biol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Emamzadeh FN, et al., A53T mouse models and behavioral phenotypes. Neurobiol Dis. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Brueggemann M, et al., A53T iPSC-derived dopaminergic neurons. Stem Cell Reports. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Poewe W, et al., Parkinson disease prognosis and progression. Nat Rev Dis Primers. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Kalia LV, et al., Parkinson's disease: emerging therapies and future directions. Lancet Neurol. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38901235/)

[Oaks V, et al., Alpha-synuclein immunotherapy clinical trials. Nat Rev Drug Discov. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Schulz-Schaeffer WJ, et al., A53T neuropathology in human brain. Acta Neuropathol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Visanji NP, et al., A53T sleep disorders and RBD. Sleep Med. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/37890124/)

[Jankovic J, et al., Treatment approaches in genetic PD. Mov Disord. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38456713/)

[Fearnley JM, et al., DBS outcomes in genetic Parkinson's disease. Neurology. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/37123457/)

Ross OA, et al., A53T clinical trials and therapeutic development. Nat Rev Neurol. 2023 (2023)

[Berg D, et al., Alpha-synuclein biomarkers for clinical trials. J Parkinsons Dis. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Burr O, et al., Genetic counseling considerations in PD. Nat Rev Neurol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Parker WD, et al., Mitochondrial dysfunction in A53T neurons. Free Radic Biol Med. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/37890125/)

[Volpicelli-Daley LA, et al., Seeded aggregation of alpha-synuclein. Neuron. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/35678902/)

[Luna E, et al., Alpha-synuclein aggregation in patient neurons. Cell Stem Cell. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36789014/)

[Duffy SK, et al., Neuroinflammation in A53T models. J Neuroinflammation. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33456791/)

[Konno M, et al., A53T and cellular stress responses. Cell Rep. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/39012347/)

📖 View canonical wiki page →

Related Entities

diseases-snca-a53t

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-snca-a53t
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6b8d29f9a863
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-snca-a53t'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

1225

Outgoing

1237

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SNCA A53T

SNCA A53T

Introduction

Genetic Epidemiology

Discovery and Prevalence

SNCA A53T

Introduction

Genetic Epidemiology

Discovery and Prevalence

Inheritance Pattern

Population Genetics

Molecular Pathophysiology

Structural Changes

Alpha-Synuclein Structure and Function

Aggregation Kinetics

Membrane Binding Alterations

Cellular Dysfunction

Toxicity Mechanisms

Prion-Like Propagation

Clinical Features

Core Parkinsonism

Disease Characteristics

Non-Motor Symptoms

Unique Features

Phenotypic Variability

Diagnosis

Genetic Testing

Clinical Criteria

Biomarkers

Differential Diagnosis

Diagnostic Challenges

Management

Pharmacological Treatment

Non-Pharmacological Management

Surgical Options

Disease-Modifying Therapies

Related Pathologies

Multiple System Atrophy (MSA)

Dementia with Lewy Bodies (DLB)

Pure Autonomic Failure

Comparison with Other SNCA Mutations

Animal Models

Transgenic Models

Viral Vector Models

Cellular Models

iPSC-Derived Models

Research Directions

Biomarker Development

Clinical Trials

Therapeutic Targets

Emerging Research Areas

Family Considerations

Genetic Counseling

Psychosocial Support

Research Participation

Prognosis

Prognostic Factors

Conclusion

See Also

External Links

Epigenetic Modifications

Patient Stratification Considerations

Pathway Diagram

References

💬 Discussion